FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, specifically to recombinant production of peptide antigens, and can be used in medicine to produce universal preventive vaccine against bird and human influenza A virus. Disclosed is a recombinant TM2e antigen, which is a recombinant protein with a molecular weight of 24 kDa and containing consensus for avian influenza A viruses and human M2e-epitope sequence corresponding to fragment from 2 to 24 amino acid residue of said epitope.
EFFECT: invention provides preparing the antigen component for preparing the universal bivalent vaccine against avian and human influenza A virus.
3 cl, 4 dwg, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| RECOMBINANT ANTI-INFLUENZA VACCINE WITH WIDE RANGE OF PROTECTION AND METHOD FOR ITS PREPARATION | 2017 |
|
RU2757013C2 |
| RECOMBINANT STRAIN OF INFLUENZA VIRUS A/PR8-NS124-TB10_4-2A-HSPX AND METHOD FOR SPECIFIC PREVENTION OF PULMONARY TUBERCULOSIS USING MUCOSAL VACCINE BASED THEREON | 2019 |
|
RU2726106C1 |
| STRAIN OF A RECOMBINANT PSEUDO ADENOVIRAL PARTICLE BASED ON HUMAN ADENOVIRUS GENOME OF SEROTYPE 5 Ad5-tetOFF-E3-HA125 SEROTYPE, CARRYING HAEMAGGLUTININ CONSENSUS GENE OF INFLUENZA VIRUS SUBTYPES H1, H2, H5 FOR PRODUCING INFLUENZA IMMUNOGENIC PREPARATIONS, METHOD FOR PRODUCING GENE | 2018 |
|
RU2713722C1 |
| CHIMERIC INFLUENZA VACCINES | 2021 |
|
RU2834969C1 |
| RECOMBINANT VACCINE STRAIN FOR LIVE INTRANASAL VACCINE PROVIDING COMBINED PREVENTION OF INFLUENZA AND CORONAVIRUS INFECTIONS | 2022 |
|
RU2782531C1 |
| SINGLE-DOMAIN ANTIBODY FOR NEUTRALIZING VIRUSES AND ITS MODIFICATION, AND A METHOD FOR THEIR USE FOR EMERGENCY PREVENTION OF DISEASES CAUSED BY INFLUENZA A VIRUS | 2021 |
|
RU2777073C1 |
| INFLUENZA HEMAGGLUTININ COMPOSITIONS WITH HETEROLOGOUS EPITOPES AND/OR ALTERED CLEAVAGE SITES DURING MATURATION | 2017 |
|
RU2769406C2 |
| RECOMBINANT STRAIN OF A/PR8-NS124-Luc INFLUENZA VIRUS AND METHOD FOR EVALUATING POST-VACCINAL NEUTRALIZING ANTIBODIES USING BIOLUMINESCENT DETECTION | 2019 |
|
RU2759054C2 |
| RECOMBINANT VIRUS-LIKE PARTICLES (VLP) USING BOVINE IMMUNODEFICIENCY VIRUS GROUP-SPECIFIC ANTIGEN (GAG) PROTEIN | 2016 |
|
RU2734118C2 |
| CROSS-REACTIVE RECOMBINANT HUMAN INFLUENZA A VIRUS VACCINE | 2020 |
|
RU2742336C1 |
